Form 8-K - Current report:
SEC Accession No. 0001140361-23-051009
Filing Date
2023-11-02
Accepted
2023-11-02 08:44:19
Documents
57
Period of Report
2023-11-02
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20013910_8k.htm   iXBRL 8-K 30645
2 EXHIBIT 99.1 ef20013910_ex99-1.htm EX-99.1 90404
3 EXHIBIT 99.2 ef20013910_ex99-2.htm EX-99.2 19658
7 ef20013910_ex99-1slide1.jpg GRAPHIC 83787
8 ef20013910_ex99-1slide2.jpg GRAPHIC 365406
9 ef20013910_ex99-1slide3.jpg GRAPHIC 139242
10 ef20013910_ex99-1slide4.jpg GRAPHIC 208055
11 ef20013910_ex99-1slide5.jpg GRAPHIC 187094
12 ef20013910_ex99-1slide6.jpg GRAPHIC 44591
13 ef20013910_ex99-1slide7.jpg GRAPHIC 185638
14 ef20013910_ex99-1slide8.jpg GRAPHIC 171654
15 ef20013910_ex99-1slide9.jpg GRAPHIC 159778
16 ef20013910_ex99-1slide10.jpg GRAPHIC 155922
17 ef20013910_ex99-1slide11.jpg GRAPHIC 45624
18 ef20013910_ex99-1slide12.jpg GRAPHIC 181072
19 ef20013910_ex99-1slide13.jpg GRAPHIC 183491
20 ef20013910_ex99-1slide14.jpg GRAPHIC 170901
21 ef20013910_ex99-1slide15.jpg GRAPHIC 37971
22 ef20013910_ex99-1slide16.jpg GRAPHIC 174501
23 ef20013910_ex99-1slide17.jpg GRAPHIC 152201
24 ef20013910_ex99-1slide18.jpg GRAPHIC 174073
25 ef20013910_ex99-1slide19.jpg GRAPHIC 198472
26 ef20013910_ex99-1slide20.jpg GRAPHIC 39879
27 ef20013910_ex99-1slide21.jpg GRAPHIC 175154
28 ef20013910_ex99-1slide22.jpg GRAPHIC 205306
29 ef20013910_ex99-1slide23.jpg GRAPHIC 213886
30 ef20013910_ex99-1slide24.jpg GRAPHIC 42458
31 ef20013910_ex99-1slide25.jpg GRAPHIC 212485
32 ef20013910_ex99-1slide26.jpg GRAPHIC 110568
33 ef20013910_ex99-1slide27.jpg GRAPHIC 115090
34 ef20013910_ex99-1slide28.jpg GRAPHIC 128466
35 ef20013910_ex99-1slide29.jpg GRAPHIC 215611
36 ef20013910_ex99-1slide31.jpg GRAPHIC 155925
37 ef20013910_ex99-1slide32.jpg GRAPHIC 45038
38 ef20013910_ex99-1slide33.jpg GRAPHIC 153292
39 ef20013910_ex99-1slide34.jpg GRAPHIC 126477
40 ef20013910_ex99-1slide35.jpg GRAPHIC 209600
41 ef20013910_ex99-1slide37.jpg GRAPHIC 203559
42 ef20013910_ex99-1slide38.jpg GRAPHIC 197610
43 ef20013910_ex99-1slide39.jpg GRAPHIC 174360
44 ef20013910_ex99-1slide40.jpg GRAPHIC 176122
45 ef20013910_ex99-1slide41.jpg GRAPHIC 237098
46 ef20013910_ex99-1slide42.jpg GRAPHIC 155116
47 image0.jpg GRAPHIC 6484
48 image00002.jpg GRAPHIC 99149
49 image00003.jpg GRAPHIC 102245
  Complete submission text file 0001140361-23-051009.txt   9292549

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ocup-20231102.xsd EX-101.SCH 3865
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ocup-20231102_lab.xml EX-101.LAB 22546
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ocup-20231102_pre.xml EX-101.PRE 16044
51 EXTRACTED XBRL INSTANCE DOCUMENT ef20013910_8k_htm.xml XML 4087
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Ocuphire Pharma, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 231370277
SIC: 2834 Pharmaceutical Preparations